Gut Dysbiosis as a Potential Guide for Immunotherapy (Dis)Continuation After 2 Years in NSCLC: A Brief Report [0.03%]
胃肠菌群失调可能作为免疫治疗二年后的(停药继续)指标：简短报告
Adele Bonato,Claudia Parisi,Priscilla Cascetta et al.
Adele Bonato et al.
Background: Although most phase III pivotal trials have set the duration of immune checkpoint blockers (ICB) for advanced NSCLC at 2 years, the criteria for safely discontinuing ICB remain undefined. Growing evidence link...
Direct Comparison of Tumor-Informed and Tumor-Naive Circulating Tumor DNA Assays for Recurrence Detection in Early-Stage NSCLC [0.03%]
用于早期非小细胞肺癌复发检测的肿瘤知情与肿瘤 naive 血液肿瘤dna检测的直接对比研究
Van-Anh Nguyen Hoang,Ngoc Nguyen,Tu Nguyen et al.
Van-Anh Nguyen Hoang et al.
Background: Circulating tumor DNA (ctDNA) is a promising prognostic biomarker in early-stage NSCLC. The typical tumor-informed method of ctDNA testing requires tissue specimens of high quality, which is a challenge in dev...
Preoperative Immune-Related Adverse Events in Resectable NSCLC Treated With Neoadjuvant Nivolumab Plus Chemotherapy: A Multicenter Retrospective Analysis [0.03%]
可切除NSCLC患者新辅助纳武利尤单抗联合化疗的免疫相关不良事件：多中心回顾性分析
Takuya Watanabe,Kotaro Nomura,Shinkichi Takamori et al.
Takuya Watanabe et al.
Introduction: Preoperative immune-related adverse events (irAEs) during neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer (NSCLC) remain poorly characterized. We aimed to evaluate their frequency, c...
Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for ALK- Mutated NSCLC [0.03%]
针对ROS1重排非小细胞肺癌的酪氨酸激酶抑制剂体重、体表面积、毒性及疗效分析
Beatriz Jimenez Munarriz,Sameena Khan,Katrina Hueniken et al.
Beatriz Jimenez Munarriz et al.
Introduction: ALK tyrosine kinase inhibitors (ALK TKIs) are started at a standard dose regardless of patients' weight and body surface area (BSA). In this retrospective analysis, the authors explored whether body size var...
Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial [0.03%]
无前期治疗的IV期非小细胞肺癌且ECOG评分为2至3分及高PD-L1表达患者的Durvalumab疗效（IFCT-1802 SAVIMMUNE）：一项多中心II期试验
Valérie Gounant,Laurent Greillier,Céline Mascaux et al.
Valérie Gounant et al.
Introduction: Eastern Cooperative Oncology Group performance status 2 to 3 is associated with poor survival and chemotherapy-related adverse events (AEs). The impact of poor PS on the safety and efficacy of immune checkpo...
Erratum to 'Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata' [JTO Clinical and Research Reports Volume 6 Issue 4 (2025) 100798] [0.03%]
关于“按社会人口统计学特征分期的IV期NSCLC近期生存收益”一文的勘误[JTO临床与研究报告第6卷第4期(2025年)100798]
Oluwaseun F Ayoade,Maureen E Canavan,Emily J Zolfaghari et al.
Oluwaseun F Ayoade et al.
[This corrects the article DOI: 10.1016/j.jtocrr.2025.100798.]. © 2025 The Authors.
Published Erratum
JTO clinical and research reports. 2025 Jun 3;6(12):100850. DOI:10.1016/j.jtocrr.2025.100850 2025
Jandos Amankulov,David F Yankelevitz,Amangeldi Mukhamejan et al.
Jandos Amankulov et al.
The First Central Asian Forum on Lung Cancer was held at the National Academy of Sciences of the Republic of Kazakhstan on April 8 and 9, 2025. Organized by the Kazakhstan Cancer Society, KazIOR, and the I-ELCAP/IELCART consortia, the forum...
Gowri Swaminathan,Jonathan Muratori,Faateh Rauf et al.
Gowri Swaminathan et al.
Solitary fibrous tumors (SFTs) can be either localized or metastatic. We present a rare case of a 69-year-old patient with a metastatic solitary fibrous tumor in uncommon anatomical locations, treated with a short course of pazopanib. While...
DESTINY of Immunotherapy in Patients With HER2 Mutant Lung Cancer: Case Report [0.03%]
免疫治疗在HER2突变型肺癌患者中的应用案例报告
Lorenza Landi,Francesca Fusco,Enrico Melis et al.
Lorenza Landi et al.
Immunotherapy has significantly transformed the landscape of non-oncogene-driven NSCLC. Multiple trials have reported that immunotherapy, either alone or in combination with chemotherapy, can induce pathologic complete responses-essentially...
Addressing Global Disparities in Lung Cancer Screening: Lessons From Puerto Rico and Beyond [0.03%]
从波多黎各等地开展肺癌筛查的经验对全球不均衡的应对策略有何启示？
Patrick Goodley,Matthew Evison
Patrick Goodley